Generics Growth Strategies: Cost containment and M&A shape the global generics industry - 2009/09/03 - Business Insights

Report title: Generics Growth Strategies: Cost containment and M&A shape the global generics industry

from Business Insights
129 page report published Sep 03, 2009

Price $3,835.00 available for immediate download

Report Overview

Table of Contents

Search Inside

About Business Insights

IntroductionThe last three years has seen several major shifts in generics company strategies. From 2006 to 2008 a period of high M&A activity was seen as many companies sought to expand geographically and create the scale required to compete with large pharmaceutical companies. Since the global financial crisis the level of deals has declined due to the implications of restricted debt markets and the need to reduce company debt.The global financial crisis has also affected government debt and subsequently healthcare cost containment has become a prominent issue. Many nations and in particular the US is seeking to reduce healthcare costs through promotion of generics and creating better approval pathways for biogenerics.Key findings
- The unbranded pharmaceutical industry grew from $41,476m in 2007 to $44,364m in 2008, a 7.0% annual growth.
- Teva took over the position of global generics leader showing impressive growth of 24.0% and sales of $7,015m for 2008. The company gained considerable market share particularly in the US.
- Latin America was the fastest growing region with a 2007-08 annual growth rate of 28.7% and a 2004-08 CAGR of 36.8%. This was predominantly due to the largest Latin American market, Brazil, which grew with a 2004-08 CAGR of 41.1%.Key features of this report
- Evaluation of the unbranded generics market from 2004-08 in terms of sales.
- Country and region specific analysis of the generics market in terms of sales.
- Therapy area analysis including company and product level breakdown by sales.
- Identify trends in M&A strategies including case studies of major M&A deals from 2005 onwards.Use this report to
- Understand the generic pharmaceutical market dynamics.
- Learn about issues driving and resisting growth for generics companies.
- Gain insight into growth strategies employed by the Top 10 generics players.
- Target geographic focus through detailed analysis of countries and regions.
- Be informed on growth driving and growth resisting therapy areas and molecule typesDiscover
- What effect has the global financial crisis had on the generics industry?
- What growth strategies have leading generics players utilised and how effectively?
- How has M&A activity shaped the generics industry?
- Which therapy areas are providing the strongest growth for generics companies?

Source:

Business Insights

Document ID:

rbhc0239

Industry:

Pharmaceutical

Free Sample:

Click Here to Download

Format:

PDF

Title	Starting Page	Number of Pages
Sections
Table of Contents Generics Growth Strategies Executive summary 11 Generics growth drivers and resistors 11 Consolidation within the generics industry 12 The generics industry by country and region 12 Therapy area analysis 13 Leading generics pharma compani	0	1
Table of Contents	0	1
Generics Growth Strategies	0	1
Executive summary 11	0	1
Generics growth drivers and resistors 11	0	1
Consolidation within the generics industry 12	0	1
The generics industry by country and region 12	0	1
Therapy area analysis 13	0	1
Leading generics pharma companies 14	0	1
Chapter 1 Generics growth drivers and resistors 17	0	1
Summary 17	0	1
Introduction 18	0	1
Growth drivers for generics 19	0	1
Company growth opportunities 19	0	1
Growth through paragraph IV challenges 19	0	1
Generic biologics 22	0	1
Mergers and acquisitions 23	0	1
External factors influencing generics growth 23	0	1
Healthcare cost containment 23	0	1
Improving drug approval pathways 25	0	1
Improving the biosimilars approval pathway 27	0	1
Threats to the generics industry 29	0	1
Patent litigation 29	0	1
Reformulation 30	0	1
DTC and Rx to OTC switching 31	0	1
Authorized generics and in-house generics 32	0	1
Chapter 2 Consolidation within the generics industry 35	0	1
Summary 35	0	1
Introduction 36	0	1
M&A strategies 36	0	1
Manufacturing facilities 37	0	1
Economies of scale 37	0	1
Generic biologics 38	0	1
Therapeutic expansion 38	0	1
Drug technology access 38	0	1
Geographic expansion and diversification 40	0	1
Selected M&A deals 41	0	1
Actavis 41	0	1
Acquisition of Alpharma 42	0	1
Acquisition of Amide 42	0	1
Acquisition of Sindan 42	0	1
Acquisition of Keri Pharma 43	0	1
Apotex 43	0	1
Acquisition of Lareq 43	0	1
Acquisition of Topgen 43	0	1
Daiichi Sankyo 44	0	1
Acquisition of Ranbaxy 44	0	1
Dr. Reddyâ€™s 46	0	1
Acquisition of Betapharm 46	0	1
Acquisition of Rocheâ€™s API facility 47	0	1
Acquisition of Trigenesys 47	0	1
Hospira 47	0	1
Acquisition of Mayne Pharma 48	0	1
Mylan 48	0	1
Acquisition of Matrix Laboratories 49	0	1
Acquisition of Merck KGaAâ€™s generics business 50	0	1
Novartis (Sandoz) 51	0	1
Acquisition of Sabex 51	0	1
Acquisition of Hexal and Eon 51	0	1
Ratiopharm 51	0	1
Acquisition of Magnafarma 52	0	1
Acquisition of Pulmotec and Ribosepharm 52	0	1
Sanofi-Aventis (Winthrop) 52	0	1
Acquisition of Zentiva 52	0	1
Acquisition of Laboratorios Kendrick 53	0	1
Stada 53	0	1
Acquisition of Hemofarm 54	0	1
Acquisition of Nizopharm 54	0	1
Other acquisitions 54	0	1
Teva 55	0	1
Acquisition of Barr 55	0	1
Acquisition of Ivax 56	0	1
Watson 57	0	1
Acquisition of Arrow 57	0	1
Acquisition of Amarin 58	0	1
Acquisition of Sekhsaria 58	0	1
Acquisition of Andrx 59	0	1
Conclusion 59	0	1
Chapter 3 The generics industry by country and region 63	0	1
Summary 63	0	1
Introduction 64	0	1
North America 68	0	1
Five major European markets 70	0	1
Central and Eastern Europe 72	0	1
AsiaPac 73	0	1
Japan 74	0	1
China 75	0	1
Other selected AsiaPac markets 76	0	1
Latin America 76	0	1
Chapter 4 Therapeutic analysis of the generics industry 81	0	1
Summary 81	0	1
Introduction 82	0	1
CNS market 85	0	1
Leading generics companies by sales 85	0	1
Top selling molecules 86	0	1
Cardiovascular market 88	0	1
Leading generics companies by sales 88	0	1
Top selling molecules 90	0	1
Anti-infectives market 91	0	1
Leading generics companies by sales 91	0	1
Top selling molecules 92	0	1
Alimentary tract and metabolism market 93	0	1
Leading generics companies by sales 94	0	1
Top selling molecules 95	0	1
Oncology market 96	0	1
Leading generics companies by sales 96	0	1
Top selling molecules 97	0	1
Chapter 5 Leading generics companies 101	0	1
Summary 101	0	1
Introduction 102	0	1
Sales analysis of key generics players 102	0	1
Unbranded generics sales 102	0	1
Branded and unbranded focus 104	0	1
Regional analysis of leading generics players 105	0	1
Company portfolio and strategic analysis 108	0	1
Teva 108	0	1
Selected news & events 109	0	1
Mylan 109	0	1
Selected news & events 111	0	1
Novartis (Sandoz) 111	0	1
Selected news & events 112	0	1
Ratiopharm 112	0	1
Selected news & events 113	0	1
Watson 114	0	1
Selected news & events 115	0	1
Stada 115	0	1
Selected news & events 117	0	1
Hospira 117	0	1
Selected news & events 118	0	1
Apotex 119 Selected news & events 120 Servier 121 Pfizer (Greenstone) 121 Selected news & events 123 Future Outlook 124 Cost containment 124 Outperforming branded pharmaceuticals 124 Biogenerics/Biosimilars 125 Loss of price advantage and low cost manufact	0	1

Enter the keyword(s) which you would like to search for within this document and click "Search"

Business Insights provides a single, off-the-shelf, objective source of data, analysis and market insight. Business Insights work in association with leading industry experts to produce a range of reports across a wide range of industry sectors.

Price: $3,835.00

Free Sample

Questions about
this research?

Send page to a friend

Return to
Alacra Company Snapshot

Can't Decide?

Purchasing premium research sight unseen can be intimidating. At Alacra we want you to know what you are getting. Visit our FAQ or ask our Customer Service Team any questions about the report you are considering purchasing.